Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trabectedin versus gemcitabine in pretreated advanced leiomyosarcoma
2024-513820-40-00Phase 2Authorised
- Sponsor
- Italian Sarcoma Group
- Start
- Oct 2021
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in leiomyosarcoma (LMS) comparing Trabectedin with Gemcitabine (2 arms). Primary endpoint: Growth Modulation Index. Planned start Oct 2021; status: authorised.
02
Drugs
trabectedingemcitabine
03
Conditions
leiomyosarcoma (LMS)
Beyond the preview
Go deeper on 2024-513820-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513820-40-00.